Literature DB >> 31456235

The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?

Joyce Wy Mak1, Joseph Jy Sung1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31456235     DOI: 10.1111/jgh.14817

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


× No keyword cloud information.
  4 in total

1.  Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Bing Zhang; Alakh Gulati; Omeed Alipour; Ling Shao
Journal:  J Crohns Colitis       Date:  2020-10-05       Impact factor: 9.071

Review 2.  Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products.

Authors:  Karma Yeshi; Roland Ruscher; Luke Hunter; Norelle L Daly; Alex Loukas; Phurpa Wangchuk
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

3.  Schistosoma japonicum peptide SJMHE1 inhibits acute and chronic colitis induced by dextran sulfate sodium in mice.

Authors:  Wenqi Shan; Wenzhe Zhang; Fei Xue; Yongbin Ma; Liyang Dong; Ting Wang; Yu Zheng; Dingqi Feng; Ming Chang; Guoyue Yuan; Xuefeng Wang
Journal:  Parasit Vectors       Date:  2021-09-06       Impact factor: 3.876

4.  Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study.

Authors:  Xiao-Qi Ye; Jing Cai; Qiao Yu; Xiao-Cang Cao; Yan Chen; Mei-Xin Rao; Bai-Li Chen; Yao He; Zhi-Rong Zeng; Hao Chen; Yi-Mou Lin; Qian Cao; Min-Hu Chen; Sheng-Hong Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.